ema retatrutide approval shows promise for weight loss and is rumored to be stronger than Ozempic or Mounjaro but is not yet approved by regulatory bodies like the FDA, meaning its long-term safety and full risk Why Retatrutide Is Gaining Attention

BMC Cancer 23 , 594 (2023)

Intensity Preservation While volume decreases, intensity should remain high

The absence of early side effects does not by itself mean a medication is failing, and noticeable nausea is not proof that a medication is "working better." What may feel different during the first week

GLP-1 medicationsshort for glucagon-like peptide-1 receptor agonistsare prescription drugs that help regulate appetite, slow digestion, and improve blood sugar control

Depending on the makeup of their patient base, providers may need to navigate patient therapy discontinuation and a change in payer mix that could impact revenue

Another meta-analysis, which looked at relevant data from multiple clinical studies, estimated that 40-70% of people on GLP-1 drugs will experience nausea at some point while taking the medication